How Do We Manage Chronic Lymphocytic Leukemia in India.

IF 2.7 3区医学 Q2 HEMATOLOGY

Current Hematologic Malignancy Reports Pub Date : 2024-04-01 Epub Date: 2024-02-01 DOI:10.1007/s11899-023-00722-7

Parathan Karunakaran, Nidhi Jain, Deepesh P Lad

{"title":"How Do We Manage Chronic Lymphocytic Leukemia in India.","authors":"Parathan Karunakaran, Nidhi Jain, Deepesh P Lad","doi":"10.1007/s11899-023-00722-7","DOIUrl":null,"url":null,"abstract":"Purpose of review: Chronic lymphocytic leukemia was an ignored leukemia in India until a decade back, given its low prevalence and absence of novel drugs to treat it. Healthcare in India is heterogeneous, with variations in population, health systems, and reimbursement options. We have focused on opinions from three hemato-oncologists incorporating an opinion poll from 44 hemato-oncologists across India on the common issues in CLL to give an idea of the practice pan-India.Recent findings: More CLL patients are being diagnosed in their early stages. There is an attempt to use prognostic and predictive markers in making shared decisions for managing CLL. There is still a role for chemoimmunotherapy (CIT) in India, given limited health insurance coverage. But with the availability of inexpensive generics, the patient preference for non-CIT options like Bruton's tyrosine kinase (BTK) inhibitors is palpable. The CLL scene in India is changing rapidly. With the wide availability of economical generic small molecule inhibitors, monoclonal antibodies, and coverage by social health insurance schemes, India is poised to cater to most CLL patient needs.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-023-00722-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Chronic lymphocytic leukemia was an ignored leukemia in India until a decade back, given its low prevalence and absence of novel drugs to treat it. Healthcare in India is heterogeneous, with variations in population, health systems, and reimbursement options. We have focused on opinions from three hemato-oncologists incorporating an opinion poll from 44 hemato-oncologists across India on the common issues in CLL to give an idea of the practice pan-India.

Recent findings: More CLL patients are being diagnosed in their early stages. There is an attempt to use prognostic and predictive markers in making shared decisions for managing CLL. There is still a role for chemoimmunotherapy (CIT) in India, given limited health insurance coverage. But with the availability of inexpensive generics, the patient preference for non-CIT options like Bruton's tyrosine kinase (BTK) inhibitors is palpable. The CLL scene in India is changing rapidly. With the wide availability of economical generic small molecule inhibitors, monoclonal antibodies, and coverage by social health insurance schemes, India is poised to cater to most CLL patient needs.

Abstract Image

查看原文本刊更多论文

我们如何管理印度的慢性淋巴细胞白血病？

综述目的：由于慢性淋巴细胞白血病发病率低，且缺乏新型药物治疗，因此直到十年前，慢性淋巴细胞白血病在印度还是一种被忽视的白血病。印度的医疗保健情况各不相同，人口、医疗系统和报销方案也各不相同。我们重点研究了三位血液肿瘤专家的意见，并结合印度 44 位血液肿瘤专家对 CLL 常见问题的意见调查，以了解全印度的实践情况：最近的发现：越来越多的 CLL 患者在早期阶段得到诊断。最近的发现：越来越多的 CLL 患者在早期阶段就被确诊，人们尝试使用预后和预测指标来共同决定如何管理 CLL。由于医疗保险覆盖面有限，化学免疫疗法（CIT）在印度仍有用武之地。但随着廉价非专利药的出现，患者对布鲁顿酪氨酸激酶（BTK）抑制剂等非 CIT 方案的偏好显而易见。印度的 CLL 领域正在迅速发生变化。随着经济型非专利小分子抑制剂、单克隆抗体的广泛供应以及社会医疗保险计划的覆盖，印度有望满足大多数 CLL 患者的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.